Clinical Trials
24 trialsPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Janssen Research & Development, LLC
DIVINE
Mayo Clinic
ASpiRE
Institute of Cancer Research, United Kingdom
TRIPLE-SWITCH
Canadian Cancer Trials Group
VA STARPORT
VA Office of Research and Development
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Cedars-Sinai Medical Center
APPROACH
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
HEATWAVE
Jonsson Comprehensive Cancer Center
TherApeutics in Early ProState Cancer (TAPS02)
Cambridge University Hospitals NHS Foundation Trust
ProBio
Karolinska Institutet
STAPLE
A.O.U. Città della Salute e della Scienza
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
GUNS
University of British Columbia
FINPROVE
Helsinki University Central Hospital
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School